ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1452	National Cancer Institute	Html	en	Cigarette Smoking: Health Risks and How to Quit (PDQ®)–Health Professional Version	Expert-reviewed information summary about research and guidelines focused on the prevention and cessation of cigarette smoking.	smoking cessation strategy 0.633721 smoking cessation rates 0.605741 quit attempt 0.552085 effective smoking cessation 0.580922 gradual cessation group 0.483049 abrupt cessation 0.562882 prolonged validated smoking 0.480554 lung cancer 0.658405 tobacco cessation 0.463262 smoking cessation pharmacotherapies 0.597527 abrupt smoking cessation 0.601297 pipe tobacco smoking 0.505275 current smoking 0.475722 gradual cessation arm 0.465437 nicotine replacement therapy 0.54532 randomized trial 0.492165 Smoking cessation counseling 0.609156 receptor partial agonist 0.460896 area-level smoking prevalence 0.513667 smoking reduction 0.49426 smoking behavior 0.469981 smoking cessation treatment 0.588411 smoking prevalence data 0.513642 tobacco products 0.485537	abrupt cessation arm 0.472163 smoking cessation 0.926558 vs abrupt cessation 0.475821 adult cigarette smoking 0.474818 gradual cessation method 0.466403 cigarette smoking cessation 0.573293 cigarette smoking 0.62168 smoking cessation pharmacotherapy 0.595082 varenicline 0.542592 tobacco smoking 0.505702 smoking cessation rate. 0.602815 gradual cessation 0.501212 abrupt cessation group 0.489713 nicotinic acetylcholine receptor 0.464069 self-reported smoking abstinence 0.502629 smoking abstinence 0.574891 cigarette smoking prevalence 0.566333 randomized controlled trial 0.482431 6-month cessation rates 0.474432 nicotine patch 0.531368 smoking cessation intervention 0.590903 usual smoking patterns 0.480697 lung cancer mortality 0.510576 varenicline group 0.534998	CLICK HERE
1612	National Cancer Institute	Html	en	Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of renal pelvis and ureter transitional cell cancer.	general cancer information 0.245004 treatment 0.36943 cancer treatment 0.274834 new cancer treatments 0.244453 NCI-supported cancer 0.252295 cancer cells 0.305937 cancer spreads 0.254859 body 0.283889 diagnose transitional cell 0.268084 Cancer Information Service 0.245843 PDQ cancer information 0.2892 Recurrent transitional cell 0.259741 segmental resection 0.252407 kidney 0.248946 clinical trial search 0.276195 treatment clinical trials 0.260027 National Cancer Institute 0.300743 clinical trials 0.500017 Ureter Treatment 0.280286 metastatic transitional cell 0.241447 PDQ Transitional Cell 0.249302 cancer information summary 0.272322 clinical trial 0.418117 new treatment 0.269914	breast cancer prevention 0.240544 renal cell cancer 0.301024 ureter 0.545878 patients 0.265691 Blood. The cancer 0.243945 Cell Cancer Treatment 0.266901 PDQ summary 0.241392 treatment clinical trial 0.245285 kidney cancer 0.240494 NCI PDQ cancer 0.250983 cancer research process 0.24139 cancer clinical trials 0.286739 tests 0.24917 stage 0.247801 certain pain medicines 0.268283 tumor 0.244567 treatment options 0.255801 cancer information summaries 0.244613 Treatment Editorial Board 0.244593 comprehensive cancer information 0.244987 renal pelvis 0.969529 standard treatment 0.251972 General information 0.241791	CLICK HERE
1682	National Cancer Institute	Html	en	Family Caregivers in Cancer: Roles and Challenges (PDQ®)–Health Professional Version	Expert-reviewed information summary about the challenges faced by family caregivers of cancer patients. This summary focuses on typical caregiver roles and concerns, and helpful interventions for caregivers.	caregiver strain 0.637562 caregiver self-efficacy 0.583778 caregiver involvement 0.610915 cancer care facility 0.578352 palliative care consultation 0.608288 caregiver knowledge 0.586068 Hispanic caregivers 0.676204 caregiver 0.821035 Caregiver quality 0.603509 white caregivers 0.639176 health care providers 0.59721 specialist-level palliative care 0.56948 caregiver well-being 0.592799 patient symptom care 0.583377 culturally competent care 0.564531 patients 0.715455 cancer patients 0.703941 Asian American caregivers 0.689382 caregiver emotional health 0.625075 secondary informal caregivers 0.653486 caregiver burden 0.63516 caregiver’s information 0.595277 symptom management 0.696609 orient caregivers 0.633121 primary caregiver 0.613245	caregiver portion 0.581896 African American caregivers 0.664952 caregiver needs 0.592313 end-of-life care 0.586635 family caregivers 0.726566 study 0.578902 problem-solving intervention 0.564815 bereaved caregivers 0.642182 palliative care 0.6279 tailored caregiver interventions. 0.613747 African American patients 0.595756 caregivers 0.977146 terminally ill patients 0.564522 studies 0.568233 empowers caregivers 0.628512 caregiver roles 0.620453 minority caregivers 0.663649 emotional support 0.572233 home care workers 0.567134 Caregivers report 0.630818 Caregiver assessment 0.592589 family caregiver 0.60516 cancer patient 0.576832 difficult caregiver responsibilities 0.601191	CLICK HERE
1790	National Cancer Institute	Html	es	Trastornos del sueño (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca de las causas y manejo de los trastornos del sueño en las personas con cáncer.	menudo causa problemas 0.738807 TCC ayuda 0.533662 pequeño número 0.542064 siguientes aspectos 0.690699 siguientes elementos 0.547894 leucemia linfocítica aguda 0.539982 sudores nocturnos 0.6269 siguientes cambios 0.544948 menor número 0.522208 Frecuencia respiratoria 0.534403 fase monr 0.549571 salud afectarán 0.52618 National Cancer Institute 0.522679	sueño mejora 0.68532 siguientes riesgos 0.520223 sueño mor 0.930755 Instituto Nacional 0.543079 siguientes problemas 0.588617 siguientes funciones 0.571878 Physician Data Query 0.591028 fase mor 0.552867 PDQ Trastornos 0.547079 auto hipnosis 0.530427 numerosas razones 0.546303 solo relajarme 0.534672	CLICK HERE
1822	National Cancer Institute	Html	es	Tratamiento del linfoma no Hodgkin infantil (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del linfoma no Hodgkin infantil.	LNH sobrevivirán 0.259398 Zimmermann M 0.292078 Pediatric Non-Hodgkin Lymphoma 0.307431 with b-cell 0.245734 células t 0.360685 large cell lymphoma 0.592792 large b-cell lymphoma 0.310638 Burkitt lymphoma 0.390944 anaplastic large-cell lymphoma 0.391142 B-cell lymphoma treated 0.259053 Gerrard M 0.253938 Burkitt's lymphoma 0.311811 Non-Hodgkin Lymphoma Staging 0.255329 linfoma folicular tipo 0.251963 childhood t-cell lymphoblastic 0.240771 Leuk Lymphoma 0.317156 Perkins SL 0.288471 childhood cancer 0.239116 or relapsed lymphoma 0.247628 malignant lymphoma 0.246238 Sposto R 0.298634 Non-Hodgkin Lymphoma Response 0.260692 patients with lymphoma 0.260427 group study 0.273614 estadio iv 0.240422	Cairo MS 0.242979 Pediatr Blood Cancer 0.510662 tipo burkitt células 0.244366 Cancer Group Study 0.240733 lymphoblastic lymphoma 0.400773 Clin Oncol 0.804352 B-cell non-Hodgkin 0.317262 sistema nervioso central 0.275043 childhood b-cell 0.244175 lymphoma kinase-positive 0.244682 non-hodgkin lymphoma 0.692526 Children's Cancer Group 0.319924 lymphoma clinical trials 0.248853 b-cell lymphoma 0.27822 tipo burkitt 0.265416 non-hodgkin's lymphoma 0.96423 mediastinal b-cell lymphoma 0.256031 group report 0.255665 children's oncology group 0.421119 anaplastic large cell 0.389279 Burkitt's lymphoma from 0.271141 lymphoma with tumor 0.259565 células b 0.2577 Burkhardt B 0.329473	CLICK HERE
1893	National Cancer Institute	Html	es	Tratamiento de la leucemia linfoblástica aguda infantil (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de la leucemia linfoblástica aguda infantil.	posibles efectos tardíos 0.502603 células madre 0.665076 posibles factores 0.501536 adultos jóvenes 0.501533 leucemia linfocítica aguda 0.512291 alto riesgo 0.502688 Neurofibromatosis tipo 0.502438 leucemia linfoblástica aguda 0.9746 células madre formadoras 0.506563 siguientes especialistas 0.501875 hueso compacto 0.506303 neoplasias mieloides 0.501904 remisión ayuda 0.501645 enlace drugs approved 0.513331 cromosoma filadelfia 0.525108 célula madre mieloide 0.512145 células mieloides 0.511482 células t 0.515919 efectos tardíos 0.512683 Acute Lymphoblastic Leukemia 0.513739 PDQ Efectos tardíos 0.504379 líquido cefalorraquídeo 0.536807	punción espinal.Ampliar 0.501851 National Cancer Institute 0.501144 Instituto Nacional 0.503927 célula madre linfoide 0.505893 PDQ Tratamiento 0.503921 leucemia mielógena 0.507289 siguientes signos 0.502333 nuevos tipos 0.501266 Physician Data Query 0.504088 sistema nervioso central 0.50205 linfocitos t 0.507752 siguientes terapias 0.501163 leucemia mieloide aguda 0.536874 siguientes enlaces 0.501056 célula madre 0.527864 células sanguíneas maduras 0.513427 analizarse.Este procedimiento 0.501709 consolidación /intensificación 0.531485 Filadelfia".Ampliar Cromosoma Filadelfia 0.504086 ósea elabora células 0.51533 siguientes sumarios 0.503486 siguientes pruebas 0.502205	CLICK HERE
3523	National Cancer Institute	Html	es	Estudio NCI-MATCH (Análisis Molecular para Selección de Tratamientos)	Información sobre el estudio del NCI: Análisis Molecular para Selección de Tratamientos (NCI-MATCH), en el cual los investigadores examinarán tejidos de tumor de pacientes con tumores sólidos y linfomas avanzados que han dejado de responder al tratamiento.	Tumor Profiling 0.554625 estudio match 0.941659 Investigación Oncológica 0.6022 MD Anderson 0.61416 Memorial Sloan-Kettering Cancer 0.578519 Clinical Trials 0.539697 posibles participantes 0.607033 C2 MET 0.546519 Life Sciences 0.627896 laboratorios foundation medicine 0.56991 Foundation Medicine 0.623082 Memorial Sloan-Kettering identificarán 0.577406 estudio comet 0.807536 Grupo Cambio 0.537516 met amp crizotinib 0.576245	como los costos 0.539059 seguro médico 0.533808 Cancer Center 0.605302 MD Anderson Cancer 0.572606 tratamiento inscribirán 0.618222 sk crizotinib 0.541473 cabo estudios 0.534561 Caris Life Sciences 0.579205 Investigación Oncológica ECOG-ACRIN 0.571301 Memorial Sloan-Kettering 0.625566 egfr mut afatinib 0.573282 NRG Oncology Group 0.568484 Iniciativa de Medicina 0.538366 Life Sciences identificarán 0.57351	CLICK HERE
15802	National Cancer Institute	Html	null	About the Blue Ribbon Panel	Information about the Cancer Moonshot Blue Ribbon Panel of experts. The panel was established to ensure the Cancer Moonshot's goals and approaches are grounded in the best science.			CLICK HERE
16599	National Cancer Institute	Html	es	Actividad física y cáncer	Hoja informativa que resume la evidencia que relaciona el ejercicio y otras actividades físicas, incluso el trabajo y tareas domésticas, para reducir los riesgos de cáncer.	physical activity trials 0.609757 with risk 0.60318 12). La actividad 0.606743 actividad física. Estas 0.606316 British Journal 0.604503 Jochem C 0.601681 Breast Cancer Research 0.606153 Leitzmann MF 0.603331 vigorous physical activity 0.609704 Polyp Prevention Trial 0.601597 mortality among breast 0.602477 physical activity guidelines 0.609758 physical activity with 0.609915 postdiagnosis physical activity 0.608948 7). La actividad 0.606768 Internal Medicine 0.603799 distal colon cancers 0.601731 actividad física 0.987182 PubMed Abstract 0.847996 NIH-AARP Diet 0.601986 Clinical Oncology 0.601841 Cancer Journal 0.605637 International Journal 0.60436 Courneya KS 0.60156 Does physical activity 0.60988	actividad física. La 0.606304 Arem H 0.601596 cancer prevention 0.614687 Schmid D 0.60334 semana. La actividad 0.606319 British Medical Journal 0.601693 Behrens G 0.608768 física causa cáncer 0.609492 gastrointestinal cancers 0.608366 Health Study 0.605366 Cancer Research 0.607712 actividad física. Sin embargo 0.606177 reducción promedio 0.602018 breast cancer 0.663645 Cancer Survivorship 0.604816 systematic review 0.658042 Keimling M 0.603345 physical activity 0.836944 Eliassen AH 0.601741 mejores resultados 0.60425 Cancer Institute 0.60845 Colditz GA 0.601647 Ballard-Barbash R 0.60156 recreational physical activity 0.616085	CLICK HERE
16695	National Cancer Institute	Html	en	Exceptional Responders Initiative: Questions and Answers	NCI has embarked on the Exceptional Responders Initiative to understand the molecular underpinnings of exceptional responses to treatment, primarily via chemotherapy, in cancer patients.	Available tumor tissue 0.569626 interpretable sequencing data 0.508921 molecular characterization data 0.448382 tissue 0.682864 exceptional response 0.726518 clinical data 0.520236 additional medical conditions 0.442297 Genome Sequencing 0.47304 NCI Adult CIRB 0.443946 bladder cancer 0.458992 advanced sequencing techniques 0.482454 clinical trials 0.50225 Exceptional Responders Initiative 0.704836 clinical trial 0.614538 usable genomic sequencing 0.494954 mRNA sequencing 0.489887 prior tissue 0.461175 patients 0.547684 normal tissue 0.467725 malignant tissue 0.514104 genomic sequencing data 0.583786 Exceptional Responders study 0.609387 exceptional responder definition 0.533195 tissue needs 0.459244	tumor tissue 0.673639 exceptional responses 0.550034 exceptional responder case 0.637888 Web-based clinical data 0.459426 later-phase clinical trials 0.47033 responder case identification 0.442725 National Cancer Institute 0.44916 Exceptional Responders Data 0.587384 partial response 0.553124 Tumor treatment history 0.473817 complete response 0.575098 Response Evaluation Criteria 0.47452 exceptional responders 0.907488 Core Resource facility 0.528106 Data Access Request 0.442704 interpretable genomic sequencing 0.494665 clinical trial data 0.50513 paraffin-embedded tissue 0.442416 similarly treated patients 0.476935 clinical research data 0.463293 certain molecular features 0.447952 potential exceptional responder 0.522095 whole-exome sequencing 0.464948 Biospecimen Core Resource 0.534633	CLICK HERE